Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis

Michael Kreuter; Toby M. Maher; Wim Wuyts; Claudia Valenzuela; Michael R Hamblin; Sinae Kim; Aditya Patel; Brandon Elpers; Luca Richeldi

doi:10.1016/j.chest.2025.04.003

Related publications

Article2025

Effect of Admilparant (BMS-986278), an oral LPA1 antagonist, on time to disease progression in patients with pulmonary fibrosis: a post hoc analysis of a randomized trial

Michael Kreuter, Toby M. Maher, Wim Wuyts, Claudia Valenzuela, Michael R Hamblin, S Kim, Aditya Patel, Brandon Elpers, Luca Richeldi

Article1993

A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression

Ariela Benigni, Carla Zoja, Daniela Corna, Silvia Orisio, Lorena Longaretti, Tullio Bertani, Giuseppe Remuzzi

Article2022

The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial

Roxana Mehran, Philippe Gabríel Steg, Marc A. Pfeffer, Karola Jering, Brian Claggett, Eldrin F. Lewis, Christopher B. Granger, Lars Køber, Aldo Maggioni, Douglas L. Mann, John J.V. McMurray, Jean‐Lucien Rouleau, Scott D. Solomon, Grégory Ducrocq, Otávio Berwanger, Carmine G. De Pasquale, Ulf Landmesser, Mark C. Petrie, David Sim Kheng Leng, Peter van der Meer, Martin Lefkowitz,

Article2011

TNF-receptor 1 ameliorates disease progression of Nemo-mediated hepatitis

Anju Singh, FJ Cubero, Erawan Borkham‐Kamphorst, Mark V. Boekschoten, M Al-Masaoudi, Christian Liedtke, Tom Luedde, Ralf Weiskirchen, Madeleine Müller, Mathias Heikenwälder, Christian Trautwein

Article1996

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.

David J. Evans, Peter J Barnes, Stephen M. Spaethe, E. L. van Alstyne, Melissa Mitchell, Brian O’Connor